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A B S T R A C T   
Biologic therapeutics are the medicines of the future and are destined to transform the approaches by which the 
causes and symptoms of diseases are cured and alleviated. These approaches will be accelerated through the 
development of novel strategies that target multiple pharmacologically active sites using a combination of 
different biologics, or mixtures of biologics and small molecule therapeutics. However, for this potential to be 
realised, advancements in co-formulation strategies for biologic therapeutics must be established. This review 
describes the current and emerging developments within this field and highlights the challenges and potential 
solutions, that will pave-the-way towards their clinical translation.   
1. Current state-of-art 
Biologics are macromolecular pharmaceuticals, such as peptides, 
enzymes, antibodies, antibody fragments, synthetic proteins, antibody 
drug conjugates, vaccines and nucleic acid-based gene therapies. They 
are manufactured through biological processes, rather than chemical 
synthesis, due to their structural complexity [1]. The functional mac-
romolecular chemical architecture of biologics has the potential to af-
ford greater pharmacodynamic specificity and therapeutic efficacy. 
These advantages far exceed their drawbacks, which include challenges 
associated with their manufacturing, medium to long-term biologic 
stability and delivery [2]. As a result, these advantages are accelerating 
the research and development efforts to produce new and improved 
biologics to cure disease, or to alleviate the symptoms of disease. In 
2016, ~50% of new molecular entities approved by the FDA were 
biologics, while there were more than 800 macromolecular entities 
under development. Furthermore, the biologics market is anticipated to 
grow by 9.5% per annum (doubling approximately every 7 years), 
having been valued at $254.9Bn in 2017 and is expected to reach 
$580.5 Bn by 2026 [3]. 
1.1. Biologic challenges 
The structural complexity of biologics provides downstream chal-
lenges in the formulation of these therapeutics. The challenges are 
predominantly associated with stability and delivery, as well as their 
characterization for changes in structural integrity [4]. Biologics are 
typically polymers of repeating monomer units e.g. amino-acids, 
monosaccharides & nucleosides, that are assembled into proteins, car-
bohydrates & nucleic acids. Their inherent complexity, and their ex-
istence as highly heterogeneous forms of closely related forms even 
upon purification, confirms the challenges associated with their char-
acterization and differentiation between stable and unstable ther-
apeutics. 
Biologics are susceptible to various forms of degradation, including 
aggregation, deamidation, isomerization, hydrolysis, oxidation and 
denaturation [5]. This is due to their delicate chemistry which can be 
irreversibly damaged when subjected to subtle changes in temperature, 
pH, ionic strength, as well as mechanical and chemical stimuli [6]. 
From a patient perspective, incorrectly manufactured biologics could 
lead to a loss in therapeutic efficacy and unwanted side effects. From 
the perspective of medicine development, this also leads to an increased 
cost per dose. This could be the result of an increase in dosage con-
centration required, or through additional downstream processing re-
quired to maximise product purity and quality. Therefore, the manu-
facture, storage and administration of biologics are all carefully 
controlled and regulated, to maximise therapeutic efficacy, safety, and 
commercial viability. 
Conventional control methods for limiting unwanted degradation of 
biologics during transport and storage include the use of: 1) cold chain 
storage and transport; 2) formulation with biologically and physiolo-
gically compatible buffers and excipients; and 3) freeze- and spray- 
drying to produce solid formulations of biologics [7]. More recently, 
sophisticated formulation approaches have been developed that enable 
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biologics to tolerate greater physicochemical extremes, whilst main-
taining or improving their therapeutic efficacy. Examples of such 
technologies include innovative microparticles and [8] nanoparticles 
[9], hydrogels [10] and 3D printing [11] that permit controlled and 
targeted delivery. 
In general, most biologics are delivered via injection because large 
molecules are challenging to transport across skin, mucosa & cell 
membranes. Biologics are also rapidly hydrolysed if delivered into the 
GI tract [12]. Many vaccines [13] and antibodies [14] are delivered by 
intravenous infusion, requiring administration and monitoring within a 
clinic or hospital setting, which increases the associated costs of de-
livery incurred by healthcare systems. Similarly, intra-muscular injec-
tions also require administration by a skilled person. Subcutaneous 
injections require relatively lower skill for administration and can in 
many cases even be self-administered by patients. For these reasons, 
this has become a common and preferred method of delivery [15]. 
Although delivery by injection is the most convenient method for 
biologic delivery it is not always ideal. This is primarily because of the 
pharmacokinetics of biologics, which means they are rapidly cleared 
from systemic circulation [16]. Regulatory guidelines also limit the 
volume, and so subcutaneous injections require the biologic to be at a 
high concentration so that they can be delivered in sufficiently low 
volume via pre-filled syringe. This introduces new challenges associated 
with greater susceptibility to aggregation, and increased viscosity of 
injectables [17]. As a result, multiple doses of biologic injections may 
often be required, to achieve a concentration within the therapeutic 
window that produces maximum therapeutic benefit. 
To overcome these challenges, enhanced formulations are being 
prepared that improve the methods by which biologics are delivered 
whilst augmenting their bioavailability [18]. For example, controlled 
sub-cutaneous infusion devices have been developed recently to enable 
larger volume dosage forms, although this may not be amenable to self- 
administration [19]. Furthermore, 3D printing, a future manufacturing 
technology that is leading innovations for the pharmaceutical industry, 
has already been implemented to produce diagnostics [20,21], combi-
nation therapeutics for oral delivery [22] as well as implants [23]. 
These technologies could provide sustained release of therapeutics and 
be readily translated to co-formulating biologics to provide local target 
therapy or sustained systemic action [24]. 
1.2. Landscape of co-formulation 
Co-formulation of therapeutics is an emerging strategy that aims to 
capitalise on advances in therapeutic effects observed through the co- 
administration of biologics [25]. It is important to first highlight that 
co-formulation is ambiguous terminology, and is often interchanged 
with co-administration, such that it can mean many different things 
from one individual to another. However, we have identified that the 
term combination therapy can be used to associate the main concepts of 
both co-formulation and co-administration, where the differences are 
highlighted by how and when the pharmaceuticals are delivered. 
Therefore, to clarify the terminology used in the field, a definitions map 
has for combination therapy has been produced. The landscape of de-
finitions diagram for combination therapy (Fig. 1) demonstrates how 
terminology can be clearly differentiated, to classify the breadth of 
medicinal products that are administered together. This includes se-
quential administration, co-administration, combination products, and 
co-formulation, which are described in detail in this section. 
Co-administered therapeutics are delivered at the same time, 
whereas sequentially administered therapeutics are dosed at intervals. 
Sequential administration is generally implemented to enhance ther-
apeutic efficacy, the prevention of pharmacokinetic and pharmacody-
namic drug-drug interactions [26] or where a first line therapy is sup-
ported by a second line therapy to enhance clinical outcomes [27]. 
Pharmacokinetic drug-drug interactions can be described when a 
therapeutic alters the absorption, distribution, metabolism and 
excretion of another therapeutic. Whereas pharmacodynamic drug in-
teractions can be described as when therapeutics alter the way another 
therapeutic is able to directly exert its activity at target site or induce 
biological changes that indirectly modify its activity. Where there are 
no adverse pharmacokinetic or pharmacodynamic drug-drug interac-
tions, rather a synergistic benefit, co-administration strategies are im-
plemented. 
Co-administration envelops several delivery strategies that vary in 
clinical, technical and regulatory challenge, and range from co-ad-
ministration alone, to combination products and co-formulation. Co- 
administration alone can be described as the simultaneous delivery of 
two or more existing formulations. For example, this could include 
delivery of two or more of the same dosage forms (e.g. tablet and 
capsules) or a mixture of multiple formulation types (e.g. solid dosage 
forms, suspensions and injections). This is the most common form of 
combination therapy and is implemented widely as polypharmacy for 
individuals with co-morbidities or when individuals have an advanced 
stage disease that requires more than one therapeutic for effective 
disease management. The main challenge here is optimising clinical 
efficacy, as the technical and regulatory challenges having already been 
established for the individual drug therapeutic approval processes. 
Combination products are technically challenging to produce and 
are engineered to simultaneously deliver two different therapeutics, 
that are typically of the same formulation type. Examples of innova-
tions that best describe combination products include multi-barrel 
syringes [28] or infusion bags that dispense therapeutics via a single IV 
line. The advantages of this approach are not always clear, as ther-
apeutics in existing formulations could be co-administered, which could 
overcome the dedication of resources to engineering technologies for a 
combination product. However, should the technology reduce adverse 
effects of combination therapy, whilst enhancing patient compliance 
and concordance and extending commercial rights for a product, there 
may be an incentive to consider this approach. 
Co-formulation can be considered as the purist view of a combina-
tion therapy and can be described as consisting of more than one drug 
substance in a single formulation, with the intention of delivering 
multiple therapeutic agents at the same time for maximum therapeutic 
benefit. These products should be subject to the same clinical phar-
macology studies for each of the individual new investigational drugs in 
the formulation as would be performed if the drugs were being devel-
oped independently [29]. This includes assessment of safety, bioavail-
ability, characterization of pharmacokinetics, and as a result are the 
most challenging to produce and face many obstacles to obtain a pro-
duct license in terms of demonstrable clinical efficacy, technological 
development and regulatory barriers. This is because a co-formulated 
product must not significantly impede clinical efficacy, such as phar-
macokinetic and pharmacodynamic performance, or adversely affect 
product shelf life, whilst also demonstrating marked improvement over 
co-administered therapeutics. It is important to note from our defini-
tions a biologic coformulation must consist of 2 or more drug sub-
stances, rather than a drug substance and another macromolecular 
entity such as an inactive protein, such as albumin. Albumin is classi-
fied as a pharmaceutical excipient and been implemented as a useful 
model to study co-formulation and advanced formulation strategies. 
[30,31] 
1.3. Rationale for co-formulation 
Co-formulated therapies are thought to effectively enhance clinical 
benefit, as well as extend intellectual property rights for pharmaceutical 
companies, to ensure long-term return on investment (Table 1). The 
drive to co-formulate therapeutics has been predominantly conducted 
for small molecule drugs (< 500 MW) to control the symptoms of 
chronic respiratory, cardiovascular, neurological and infectious dis-
eases. A few co-formulated biologic-based products that have been re-
cently approved or are under clinical development suggests an 
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increasing interest in industry to combine biologic therapeutic agents 
into a single dosage form (Table 2). The application of these products 
include, but are not limited to, diabetes, where the drug substances are 
short- and long-acting insulin, [32] solid tumours, where 2–6 antibodies 
targeting same or different antigens were mixed [33,34], and blood 
diseases, where 25 antibodies were mixed for the treatment of primary 
immune thrombocytopenia [35]. Therapies have also been developed 
that use a combination of small molecules and macromolecular biolo-
gics [36] for the treatment of complex infectious diseases [36,37]. An 
example of a new biologic co-formualtion is HyQvia (immune globulin 
infusion 10% (human) with recombinant human hyaluronidase), a 
once-monthly treatment for adult patients with primary im-
munodeficiency. [38] 
1.4. Clinical benefit 
The clinical benefit of co-formulated biologics is derived from en-
hancements in therapeutic efficacy, or improved patient compliance 
and concordance. Therapeutic benefit can be enhanced by targeting 
multiple pharmacologically active sites synergistically to cure or alle-
viate the acute and chronic symptoms of disease. 
This methodology has been applied to improve disease management 
for respiratory diseases, such as asthma and chronic obstructive pul-
monary diseases (emphysema and chronic bronchitis), using small 
molecule-based APIs. Here, pharmacological therapy is introduced via 
inhalers to directly prevent acute symptoms, to improve peak re-
spiratory flow, followed by long-term control, to prevent subsequent 
exacerbations. Combination therapy achieves this by combining over-
coming the short falls of short-acting bronchodilators (e.g. salbutamol, 
terbutaline) with longer acting bronchodilators and corticosteroids. 
Long-acting bronchodilators are typically β2-receptor agonists (for-
moterol and salmeterol), which relax smooth muscle and dilate re-
spiratory passages to improve airflow. Whereas long-term control is 
achieved through inhalation of corticosteroids (e.g. beclomethasone, 
budesonide, fluticasone), to improve respiratory airflow by supressing 
inflammation, oedema and secretion of obstruction mucus. 
Preparations that combine long-acting bronchodilators and corticos-
teroids include Salmeterol (salmeterol and fluticasone), Fostair (be-
clomethasone and formoterol), and Symbicort (formoterol and bude-
sonide). 
1.5. Synergistic benefit 6Cs 
Synergistic benefit of co-formulation is enhanced through the 6Cs - 
Fig. 1. The landscape of definitions diagram for combination therapy. The terminology clusters defined here can be used to group a variety of medicinal products that 
are administered together. This includes sequential administration, co-administration, combination products, co-formulation and medicinal devices. 
Table 1 
Benefits, prerequisites and risks in the development of co-formulated pharmaceuticals     
Benefit Prerequisite Risk  
Single instead of multiple drug product delivered to the patient, 
increasing compliance while reducing medical error 
Proven synergistic medical benefit and safety 
from combinational clinical trials 
Possible reduction in dosage flexibility 
Number of patients that can accept combination therapy 
could show population and disease variance 
Simplified CMC and logistics Integration in process development 
Stability of each DS does not change significantly 
in the mixture 
Analytics to characterise the degradation of 
individual drug component in the mixture 
More complex control strategy 
Availability of analytics 
Change in delivery route if co-formulated products have 
lower concentration tolerance (e.g. from SC to IV) 
Additional clinical trials are needed to prove the safety of 
co-formulated products 
New market/product differential strategy Potential IP extension of existing drugs New regulation landscape needs to be introduced 
(potential delay in BLA approval) 
DS: drug substance, CMC: Chemistry Manufacturing & Control, PK: pharmacokinetics, PD: pharmacodynamics, SC: subcutaneous, IV: intravenous, BLA: biologics 
license application.  
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Table 2 
Selection of approved and clinical studies of co-formulated biologics.     
Pharmaceutic Product and formulation detail Indication/clinical stage  
Insulin Humalog® Mix75/25™ 
Humalog® Mix50/50™ 
Eli Lilly  
1). Pre-mixed form of intermediate-acting insulin (insulin lispro protamine) and rapid- 
acting (insulin lispro) in 75:25 (Humalog® Mix75/25™) and 50:50 ratio 
(Humalog® Mix50/50™)  
2). Pre-mixed form of intermediate-acting insulin isophane (HumulinN) and rapid-acting 
regular human insulin (HumulinR) in 70:30 ratio (Humulin® 70/30)  
Each product contains a total of 100 units of rapid- and intermediate-acting insulin per mL, 
which is filled in 3 or 10 mL multi-dose vial, or 3 mL single-patient-use prefilled pen 
(KwikPen®) for subcutaneous injection 
Diabetes, approved 
Insulin + GLP-1 SQLIQUA® 100/33 
Sanofi  
Pre-mixed form of long-acting insulin analogue (insulin glargine) with GLP-1 receptor 
agonist (lixisenatide)  
The product is formulated with 100 units per mL of insulin glargine and 33 μg per mL 
lixisenatide in a 3 mL single-patient-use prefilled pen for subcutaneous injection 
Diabetes, approved 
XULTOPHY® 100/3.6 
Novo Nordisk  
Pre-mixed form of long-acting insulin analog (insulin degludec) with glucagon-like peptide 
1 (GLP-1) receptor agonist (liraglutide)  
The product is formulated with 100 units per mL of insulin degludec and 3.6 mg per mL 
liraglutide in a 3 mL single-patient-use prefilled pen for subcutaneous injection 
Diabetes, approved 
Antibody Sym004 
(Symphogen)  
1:1 mixture of antibody candidate 992 and 1024 from mSymplex EGFR-specific antibody 
repertoire 
Epithelial cancers, such as non-small-cell lung, head-and-neck, 
and brain cancers (Phase 2b completed) 
Glioblastoma (Phase 3) 
Sym013 
(Symphogen)  
Six-antibody mixture: anti-EGFR antibodies 1277 and 1565; anti-HER2 antibodies 4384 
and 4517; anti-HER3 antibodies 5038 and 5082 from Symplex antibody repertoires 
A broad range of solid tumour indications with high medical 
needs globally including breast, lung, colorectal, pancreatic and 
gastric cancer (Phase 1) 
Sym015 
(Symphogen)  
1:1 mixture of two MET-targeting mAb Hu9006 and Hu 9338 from Symplex antibody 
repertoires 
Solid tumours showing alterations and/or amplification of the 
MET proto-oncogene including certain lung cancers and 
colorectal cancer 
(Phase 2a) 
Sym029 
(Symphogen)  
Mixture of anti-FLT3, anti-AXL and anti-CD40 antibodies for the mobilization and 
activation of dendritic cells 
Cancer 
(Discovery/pre-clinical stage) 
Durvalumab + tremelimumab  
Astra Zenecca  
Mixing of durvalumab (anti-PD-L1, Imfinzi®) and tremelimumab (anti-CTLA-4). 
Durvalumab and tremelimumab were formulated into individually stable formulations and 
mixed to achieve a design space of new liquid and lyophilized co-formulations at various 
concentration ratios.  
[US Patent: 20170306025A1] 
Solid tumours (Phase1) 
Gastric cancer (Phase 2) 
Biliary tract, oesophageal (Phase 2) 
1st-line bladder cancer (Phase 3) 
2nd-line head and neck squamous cell carcinoma (Phase 3) 
1st-line hepatocellular carcinoma (Phase 3) 
Nivolumab + ipilimumab  
Bristol-Myers Squibb  
1:1 mMixing of nivolumab or pembrolizumab (anti-PD-1) to a second antibody (anti- 
CTLA4) in about 50:1, 40:1, 30:1, 20:1 10:1, 5:1, 3:1, 1:1, 1:3, 1:5, 1:10, 1:20, 1:30, 1:40 or 
1:50  
[US Patent: 20160304607A1] 
Melanoma (approved) 
Rituximab (Rituxan®) + Hyaluronidase fixed-dose combination  
Roche  
Subcutaneous injection 
Hematologic cancers (approved) 
(continued on next page) 
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Combination, Compliance, Concordance, Convenience, Carriage and 
Cure-all. 
Therapeutic efficacy can be maximised using complementary drug 
substances, where one drug substance improves the performance of 
another. An excellent example of combination therapy that implements 
this strategy is the antibiotic co-amoxiclav (Augmentin), which com-
bines two small molecule APIs amoxicillin and clavulanic acid. [39] 
Amoxicillin is a semi-synthetic derivative of penicillin that exerts its 
pharmacological effect by preventing peptidoglycans from cross-linking 
effectively during the latter stages of bacterial cell-wall synthesis. 
However, bacteria have developed strategies to inactivate penicillin- 
based antibiotics by enzymatically degrading the β-lactam ring found in 
its chemical structure, through the secretion of β-lactamase enzymes. 
Therefore, to enhance therapeutic efficacy of penicillin-based anti-
biotics, the clavulanic acid in co-amoxiclav inhibits the action of β- 
lactamases, to ‘augment’ the efficacy of amoxicillin. 
In addition to these enhancements in therapeutic benefit and effi-
cacy, patient care is also enriched through improvements in compliance 
and concordance. Compliance is improved through the elimination of 
complex therapeutic dosage regimens when more than one therapeutic 
is taken at the same time or at different times of the day. Furthermore, 
concordance is improved through effective transfer of information from 
the health care professional to the patient. For example, the healthcare 
professional only has to demonstrate the use of one inhaler, rather than 
two or more. Therefore, co-formulation is convenient for patient and 
healthcare provider alike. This convenience may also be true for the 
producer who only has to produce a single therapy, which in the long- 
term may be more economical in terms of manufacturing packing and 
carriage. It is important to mention carriage here to demonstrate the 
changes in global practices that are required to overcome accelerated 
climate change. Combined international efforts are required to slow and 
reverse increases in global temperatures, where co-formulated thera-
pies can play a role. 
Cure all, or panacea treatments, such as polyvalent vaccines are 
established examples of biologic co-formulations. Polyvalent vaccines 
prevent diseases with multiple serotypes, through the mixture of ser-
otype-specific immunogens, or by discovery and use of an immunogen 
that is conserved among serotypes. For example, the poliovirus vaccine, 
which contains three poliovirus serotypes, was first used as a polyvalent 
vaccine for reducing poliomyelitis with a success > 99% [40]. How-
ever, polyvalent vaccines bring many challenges, [41] which include 
confirmation of physical, chemical, and immunological responses, as 
well as stability, for simultaneous administration of multiple antigens, 
in comparison to the individual antigens separately [42]. In response to 
the coronavirus pandemic research and development of polyvalent 
vaccine development has accelerated. This potentially could include co- 
formulation of spike for proteins for severe acute respiratory syndrome 
coronavirus 1 & 2 (SARS-CoV, (2003) & SARS-CoV-2, (2019), respec-
tively) [43], as well as other promising platforms which include mRNA, 
DNA, non-replicating vectors, replicating vector and virus-like parti-
cles. [44] The knowledge established through the development of 
polyvalent vaccines, will form the basis for the future of co-formulated 
biologics. 
1.6. Clinical & regulatory challenges 
As co-formulated therapeutics are classified as new pharmaceutical 
entities, the clinical evaluation of the therapeutic benefit becomes in-
herently more complex. This is because additional safety concerns 
could be raised for co-formulating existing pharmaceuticals, even 
though the efficacy and safety have already been established through 
independent clinical trials. Therefore, additional clinical trials will be 
required to provide further safety and efficacy characterization of the 
co-formulated product. The clinical trial of the combination is thus 
designed based on the previous safety and efficacy data of the in-
dividual component and the dosage of the components tends to be 
fixed. A Phase III, two-arm, multicentre and randomized study is likely 
to be conducted to establish the pharmacokinetics, efficacy and safety 
of the co-formulated product, which was observed in a recently ap-
proved co-formulated product [45]. 
The co-formulation of two new co-developed drugs, however, will 
be challenging when compared to the mixing of two existing drugs. The 
Food and Drug Administration (FDA) has published guidance for the co- 
development of two investigational new drugs, that highlights the dif-
ficulty in obtaining clinical safety and efficacy data for the co-devel-
oped drugs, in comparison to data that would be obtained if they were 
developed independently. Therefore, the FDA will request for pre- 
clinical evidence that demonstrates the superiority of the co-formual-
tion over the individual components, and the reasons why each com-
ponent cannot be developed independently [29]. 
1.7. Technical challenges in therapeutic co-formulation of biologics 
The development of co-formulated products has led to innovations 
Table 2 (continued)    
Pharmaceutic Product and formulation detail Indication/clinical stage  
Pertuzumab (Perjeta®) + trastuzumab (Herceptin®) + Hyaluronidase fixed-dose 
combination  
Roche  
Subcutaneous injection 
HER-2 positive breast cancer 
(approved) 
REGN-COV2  
(Regeneron)  
Dual human IgG1 cocktail formulation 
SARS-CoV-2 virus  
Phase 3 
REGN-EB3  
(Regeneron)  
Triple human IgG1 cocktail formulation 
Ebola virus  
Under Priority Review for BLA 
Cytokines IRX Therapeutics, pipeline IRX-2 
A cell-free mixture comprised of a variety of naturally-derived cytokines, including IL-1,  
−2, −6, −8, −10, −12, TNF-α, IFN-γ and CSFs) obtained from normal, unrelated donor 
lymphocytes with potential immune-stimulatory activity 
Squamous cell carcinoma of the head and neck (Phase 2b) 
Breast cancer (Phase 2b) 
Combination products containing biologics and small molecules, such as antibody + chemotherapy drugs, have not been included.  
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in both their formulation and analysis, given the additional complexity, 
while many challenges remain. 
Non-native interactions, and the formation of heterogeneous ag-
gregates, could be major obstacles when attempting to co-formulate 
two or multiple biologics for long term storage. In the formulation 
development of single-agent products, proteins are stabilised at the 
buffer and excipient concentrations that prevent undesired interactions 
between proteins. However, to mix different proteins in solution, a 
compromise formulation may be produced, such that each mixing 
component could be relatively destabilised compared to their in-
dependent formulations. This is especially true in formulations where 
proteins in the mixture have very different preferences for pH, excipient 
type and ionic strength. Moreover, it is challenging to predict whether a 
protein in each mixture will demonstrate the same stability and de-
gradation kinetics compared to its monotherapy formulation. 
These challenges are further complicated by considering the inter-
action between the protein and the excipients, as well as the change in 
viscosity at the higher combined total protein concentration. For ex-
ample, if an anti-CTLA-4 antibody is formulated at 4.62 mg/mL and 
mixed with an anti-PD-L1 antibody of 1.54 mg/mL, the total protein 
concentration in solution for this anti-PD-1 antibody becomes 4.5 times 
higher [46]. Subcutaneous (SC) injection of biologics uses highly con-
centrated agents compared to intravenous (IV) infusion for adminis-
tration. As a result, the concentration of protein agents in SC mono-
therapy formulation could increase from 10 mg/mL up to 150 mg/mL 
[47]. This concentration could double in a combination therapy when 
drug substances are mixed in a 1:1 ratio, such that the total protein 
concentration would need to be 300 mg/mL in the solution. It is im-
portant to note the overall concentration could be further increased if 
combined in 1:2 and 1:3 ratios. 
This approach may significantly change the colloidal stability and 
protein-protein interactions of antibodies in solution that drives the 
mixture to heterogeneous aggregation. Moreover, the mixing ratio of 
the components may need to be varied to fulfil the specific dosage re-
quirements of different patient groups. This further complicates the 
stability prediction of the product of different mixing profiles. Other 
factors, such as freeze-dry processing, agitation during transportation 
and temperature change in storage, will also potentially change the 
shelf-life of the co-formulated products relative to their respective 
monotherapies. These challenges also increase the burden on the ana-
lytics used to assess product degradation for the quality control of 
products. 
For single-agent biologics, the stability, viscosity, aggregation, and 
fragmentation can be assessed using an established analytical toolkit. 
Aggregation, for example, can be analysed using a combination of size- 
exclusion chromatography (SEC) or ultraperformance size-exclusion 
chromatography (UPSEC), and light scattering methods such as static 
and dynamic light scattering (SLS & DLS), to assess the monomer re-
tention and the development of aggregation species in different for-
mulations [48–55]. Similarly, the viscosity is easily assessed using 
rheometers, or flow rates through syringe needles at constant pressure 
[56,57]. The thermal stability of the product under different pH can be 
characterised using differential scanning calorimetry (DSC) or fluori-
metry (DSF) [58–61]. Moreover, any structural alteration of the bio-
logics in different formulations and their ligand binding can be quan-
titatively assessed by circular dichroism (CD) [62,63]. 
The quality assessment and control for co-formulated biologics 
raises additional challenges compared to single-agent products, as the 
analytics must accurately characterise multiple biologics in one solu-
tion. Therefore, it would also require additional sensitivity or resolution 
to deconvolute and distinguish the signal from each component, as well 
as their respective degradation products. 
Current analytical tools demonstrate advantages and limitations 
when characterising the biological activity, molecular interaction, sta-
bility, aggregation and viscosity of proteins in co-formulations (Fig. 2). 
For example, SEC can characterise the respective monomer loss in the 
solution if the mixed proteins are not co-eluted. SEC with multi-angle 
light scattering (SEC-MALS) could further characterise the size of the 
oligomer species in the solution [64,65]. This is valuable information, 
especially for monitoring the development of early-forming aggregates. 
However, it is important to note SEC-MALS may not readily provide 
information on the identity of the aggregates. The idenitity of ag-
gregates is beneficial to understand the formulation development and 
may provide insight to whether aggregates are are formed selectively 
from only one of the biologics, or through the co-aggregation of mul-
tiple biologic species in the solution. The degradation of antibodies 
results in the fragmentation of light chain and heavy chain domains, 
which could co-elute in SEC. Furthermore, if the combined proteins 
have similar hydrodynamic radii, then the SEC method would be unable 
to separate them and therefore would only measure the total monomer 
retention. 
Additional chromatographic analytics, such as ion-exchange chro-
matography (IEC), reverse-phase liquid chromatography (RPLC) and 
hydrophobic interaction chromatography (HIC), could then be explored 
in tandem, to separate the species that are co-eluted in SEC. RPLC has 
been widely used for the separation of antibodies and their fragments. 
Although RPLC exhibits limited selectivity for closely related proteins 
when compared to IEC, it has the advantage of producing sharp and 
highly resolved separation peaks. This can be attributed to the fast- 
kinetic interactions in the reversed-phase mode. Therefore, RPLC could 
afford enhanced separations in antibodies mixtures. Similarly, HIC 
provides comparable separation to RPLC but is performed under non- 
denaturing conditions. It has been previously applied as a control 
strategy for bispecific antibodies and antibody-drug conjugates (ADC) 
[66]. However, as RPLC denatures the protein sample, it can measure 
the degree of fragmentation whereas HIC will not separate the frag-
mented heavy or light chains from the whole antibody. Therefore, HIC 
is less sensitive to map the entire degradation landscape of the proteins 
in mixture. 
Capillary electrophoresis (CE) and imaged capillary isoelectric fo-
cusing (iCIEF), separate the mixed biologics based on their charge 
heterogeneity [67,68]. These methods can be used along with chro-
matography to map out the degradation species in solution. A recent 
study of a mixture of two antibodies tested the feasibility and limita-
tions, of combining HPLC and CE in the analysis of co-formulated 
products [67]. It was previously suggested that mass spectrometry (MS) 
could be coupled to CE to characterise complex mixtures of antibodies 
[69]. This is because MS is capable of detecting weakly associated 
heterogeneous dimers in co-formulations. MS also adds sensitivity to 
characterise the molecular identity of different degradation products. 
However, none of these separation methods guarantees a non-over-
lapping separation of the co-formulated biologics and their degradation 
products. Whether these analytics fulfil the quality control requirement 
would be case specific. Therefore, it may be more promising to apply 
2D chromatography which performs two separation methods (such as 
size-based and charge-based) in tandem to characterise the co-for-
mulated system. 
Labelling of proteins with fluorescent dyes provides an extremely 
sensitive insight into the dynamics and inter-molecular interactions of 
proteins in solution. Proteins are usually labelled on primary amines, 
disulphide linkages and glycosylation sites. Non-natural amino acid 
residues can also be introduced into the sequence to provide intrinsic 
fluorescence at desired sites. However, these labels could potentially 
change the behaviour of the protein, which is undesired for control 
strategy. Labelling on primary amines is difficult to control the sites 
being labelled. It is also postulated that the charge density of labelled 
proteins can be unfavourably altered. Maleimide chemistry could cross- 
link the disulphide bond in antibodies to introduce a chemical group 
into the protein. This was previously applied to introduce a fluorescent 
dye into a nanobody for imaging, and the development of novel anti-
body-drug conjugates [70]. However, it is challenging to predict whe-
ther the labelling site could report protein-protein interactions in the 
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mixture, as disulphide bonds are usually buried within the protein 
structure. Nevertheless, it is still a very promising analytical tool to 
assess the formation of heterogeneous oligomers in the solution. 
Labelling of carbohydrate molecules on the glycosylation sites of 
proteins may have the least influence on the protein structure. 
However, the distance to the labelled site could also be too far from the 
protein-protein interaction sites, such that it is not sensitive enough to 
probe any interaction events. Moreover, it also needs to account for the 
heterogeneous glycosylation ensembles of the antibody. Finally, the 
impact of labelling on the stability and degradation of the therapeutic 
proteins must be verified before this route is taken for analytics. 
2. Future perspectives for co-formulation 
Co-formulation provides a powerful methodology to combine mul-
tiple therapeutics for maximum synergistic benefit. However, this ap-
proach, and subsequent methodological innovation, will ultimately be 
driven by clinical need. This is because preparation of more than one 
therapeutic entity is a complex process and is associated with technical, 
analytical, and regulatory challenges, which may contribute to un-
surmountable economical obstacles. Therefore, if the clinical benefit of 
the biologic co-formulation can be justified by the additional barriers, 
then co-formulation should ensue. 
Strategies are emerging, alongside small molecule therapeutics co- 
formulation, that could reduce the size of the obstacle through de-
monstration of promising proof of concept results. This can be achieved 
through the development of formulation technology, such as micro/ 
nano encapsulation and 3D printing, and of medicinal devices that take 
advantage of a variety of routes of administration, e.g. pulmonary, 
transdermal and oral delivery pathways. 
Micro and nanoparticle-based formulations possess enhanced bio-
physical properties (large surface to volume ratio), are readily ma-
nipulated through chemical modification for targeted delivery [71], 
and are able to encapsulate a variety of different small and macro-
molecular structures. As a result, they could be excellent candidates to 
co-formulate biological medicines. Continuously manufactured poly 
(lactic-co-glycolic acid) (PLGA) nanoparticles have been shown to en-
capsulate two model proteins in the form of green and red fluorescently 
labelled bovine serum albumins (BSAs) [72]. Nanoparticles demon-
strated high protein association and enhanced co-delivery of green and 
red model proteins to sub-cellular spaces, when compared non-for-
mulated proteins. Disruptive technology, such as 3D printing, has de-
monstrated strong potential in the pharmaceutical industry, to produce 
personalised and co-formulated therapeutics [22]. Poly-pills have been 
produced for small molecule APIs, each for different co-morbidities and 
tailored to a bespoke dose to maximise patient compliance con-
cordance. This formulation strategy could in-time be translated for 
biologics should they demonstrate appropriate pharmacokinetic and 
pharmacodynamic profiles. 
Typically, biologics have been administered by intravenous injec-
tion, however formulation pathways that take advantage of alternate 
non-invasive delivery pathways, such as subcutaneous, transdermal, 
implants, inhalation, oral nasal and buccal routes delivery, are being 
developed and explored [12]. Intravenous administration affords im-
mediate short-term solutions and advantages for the evaluation of 
therapeutic efficacy for co-formulated medicinal products to achieve 
clinical and regulatory approval. Although, non-invasive delivery 
methods possess research and development barriers, they present clear 
advantages in the long-term over intravenous therapy for patients, 
which include of ease administration, patient compliance and con-
cordance [73]. This facilitates translation of biologic medicine away 
from clinics and hospitals, where specialist care is required, and into 
local healthcare practices, pharmacies, and homes. 
This important transition is heavily highlighted in the literature 
methods to improve care for diabetic patients [74]. Co-formulated in-
sulin-based therapies have been developed for administration via sub-
cutaneous, transdermal [75] buccal [76] and inhalation pathways [77]. 
Non-invasive biologic therapies have seen the greatest success as co- 
formulated subcutaneous insulin products, containing long and short- 
acting analogues [78] [79], that provide a wide treatment window to 
prevent repeated administration to the patient, and suggests reasons 
why non-invasive delivery pathways are extremely attractive to de-
velop co-formulated medicines [80]. The latest developments in dia-
betes care include MultipepT1De microneedles. These microneedles use 
a mixture of co-formulated peptides from islet autoantigens to attenuate 
the autoimmune attack that is associated with the development of 
Type-1 diabetes [81]. 
Innovations in formulation and platform technologies that accel-
erate translation of co-formulated therapies from invasive to non-in-
vasive modalities, especially for those therapies which have short cir-
culation half-lives will be essential for long-term self-managed patient 
care outside of clinics. Examples of existing formulation innovations 
and platform technologies include preparations that include hyalur-
onidase and pharmaceutical implants. Hyaluronidase, like clavulanic 
acid, assists the drug substance to exert its therapeutic benefit effec-
tively. Hyaluronidase achieves this by catalysing the degradation of 
hyaluronic acid in extracellular matrices to enhance the efficacy of 
subcutaneous administration. This formulation pathway has been used 
to co-formulate subcutaneous administration of the fixed-dose combi-
nation of two monoclonal antibodies, trastuzumab and pertuzumab, in 
combination with chemotherapy in HER2-positive early breast cancer 
[45]. Whereas implants, that are also positioned sub-cutaneously, 
consisting of biologics have begun to demonstrate their strong potential 
for their ease of application, owing to their sustained release properties, 
but also their ability to protect macromolecules against degradation 
[82]. 
The fast development of co-formulated antibody products, termed 
“antibody cocktail therapy”, also demonstrates their potential in the 
treatment of viral infection. The rationale behind this is that multi- 
targeting drug substances are applied to neutralize the virus by binding 
to non-overlapping epitopes to reduce the chances of viral resistance, 
which was successfully tested in the treatment of Ebola virus infection 
[83]. With respect to the COVID-19 global public health crisis, another 
co-formulated antibody cocktail was developed with potent binding to 
Fig. 2. Venn Diagram highlighting the current analytical tools that can be ap-
plied to assess the quality control of co-formulated products. The analytics for 
either stability assessment or degradation product characterization are listed in 
blue or green circles, respectively. Analytical tools that can be applied to 
characterise both stability or degradation are presented in the overlapped zone. 
Abbreviations - DSC: differential scanning calorimetry; DSF: differential scan-
ning fluorimetry; FI: fluorescence intensity; CD: circular dichroism; SLS: static 
light scattering; DLS: dynamic light scattering; RPLC: reverse-phase liquid 
chromatography; IEC: ion-exchange chromatography; SEC: size-exclusion 
chromatography; HIC: hydrophobic interaction chromatography; MS: mass 
spectrometry; SEC-MALS: size-exclusion chromatography multiple angle light 
scattering; CE: capillary electrophoresis; iCEF: imaged capillary isoelectric fo-
cusing. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
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the SARS-COV-2 spike protein [84]. Antibody co-formulation could 
become a powerful strategy to control future virus pandemics. 
Co-formulation is an attractive therapeutic option to address mul-
tiple disease targets using two or more co-administrated pharmaceu-
ticals. From the perspective of the manufacturer, this process also can 
have the benefit of extending intellectual property protection. 
However, it is important to note, there are competing technological 
solutions, other than co-formulation, that are being developed to ef-
fectively address multiple disease targets. Although beyond the scope of 
this review, bispecific antibodies [85], which can be classified as new 
therapeutic entities and require their own research and development 
programmes and regulatory approval, are an excellent example of an-
other technology with the potential to bind and neutralize multiple 
targets in one or more diseases [86]. 
In summary, although there are many advantages proposed for co- 
formulation therapies, their development and clinical uptake is a case- 
by-case debate, whereby the patient benefits are balanced against the 
technical and regulatory limits imposed by co-formulation. 
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